Glund, Stephan <br/><br/>
Relative bioavailability of an empagliflozin 25-mg/linagliptin 5-mg fixed-dose combination tablet
.  [electronic resource] 

 -  International journal of clinical pharmacology and therapeutics  Apr 2017 
 - 355-367 p.  digital 
<br/><br/> Publication Type: Comparative Study; Journal Article; Randomized Controlled Trial 
<br/><br/><label>ISSN: </label>0946-1965 
<br/><br/><label>Standard No.: </label>10.5414/CP202929  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Administration, Oral<br/>Adult<br/>Area Under Curve<br/>Benzhydryl Compounds--administration & dosage<br/>Biological Availability<br/>Cross-Over Studies<br/>Dipeptidyl-Peptidase IV Inhibitors--administration & dosage<br/>Drug Combinations<br/>Female<br/>Germany<br/>Glucosides--administration & dosage<br/>Healthy Volunteers<br/>Humans<br/>Hypoglycemic Agents--administration & dosage<br/>Kidney Tubules, Proximal--drug effects<br/>Linagliptin--administration & dosage<br/>Male<br/>Metabolic Clearance Rate<br/>Middle Aged<br/>Sodium-Glucose Transporter 2--metabolism<br/>Sodium-Glucose Transporter 2 Inhibitors<br/>Solubility<br/>Tablets<br/>Therapeutic Equivalency